Degree in Artificial intelligence- AI
Degree in Management Information Systems- MIS
Aartificial intelligence, Analytical and Problem solving, Data Analytics, Data management, IT, Machine learning techniques, Natural Language Processing (NLP), SQL
The Role & Department
As a Senior Manager, Safety Data Management, you will become part of the Global Drug Safety and Pharmacovigilance (GDS&PV) department, where you will be responsible for safety data management activities including but not limited to configurations and maintenance of safety systems, generation of complex ad-hoc reports, and implementation and validation of safety systems and solutions.
Key responsibilities include
Perform accurate and timely configurations of safety systems (Argus) including but not limited to:
Generate line listings and tabulations from the safety system, using the reporting tool and/or SQL
Support to or author system related SOPs/Working Instructions.
Support during audits and inspections
Perform other safety system related activities, as needed or as requested by supervisor
Should be a good team player and efficiently work with other team members with PV
Requirements
The role is located in Copenhagen, DK or Utrecht, The Netherlands, or Princeton NJ, US and is a hybrid role.
For US based candidates, the proposed salary band for this position is as follows:
$114,375.00---$190,625.00
The actual salary offer will carefully consider a wide range of factors, including your skills, qualifications, experience, and location. Also, certain positions are eligible for additional forms of compensation, such as bonuses.
About You
Locations
Genmab leverages the effectiveness of an agile working environment, when possible, for the betterment of employee work-life balance. Our offices are designed as open, community-based spaces that work to connect employees while being immersed in our state-of-the-art laboratories. Whether you’re in one of our collaboratively designed office spaces or working remotely, we thrive on connecting with each other to innovate.
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Our commitment to diversity, equity, and inclusion
We are committed to fostering workplace diversity at all levels of the company and we believe it is essential for our continued success. No applicant shall be discriminated against or treated unfairly because of their race, color, religion, sex (including pregnancy, gender identity, and sexual orientation), national origin, age, disability, or genetic information. Learn more about our commitments on our website.
Genmab is committed to protecting your personal data and privacy. Please see our privacy policy for handling your data in connection with your application on our website https://www.genmab.com/privacy.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schonharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan.
Princeton, NJ, USA
2-4 year
Utrecht, Netherlands
2-4 year
Utrecht, Netherlands
6-8 year
Copenhagen, Denmark
6-8 year
Princeton, NJ, USA
6-8 year
Princeton, NJ, USA
6-8 year
Copenhagen, Denmark
6-8 year
Copenhagen, Denmark
6-8 year
Utrecht, Netherlands
6-8 year
Princeton, NJ, USA
6-8 year
Utrecht, Netherlands
6-8 year
Copenhagen, Denmark
6-8 year
Copenhagen, Denmark
6-8 year
Utrecht, Netherlands
6-8 year